Replacement of Thr32 and Gln34 in the C -terminal neuropeptide y fragment 25-36 by cis -cyclobutane and cis -cyclopentane β-amino acids shifts selectivity toward the Y4 receptor

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8422-8431

  Berlicki, Łukasz ^a,b   Kaske, Melanie ^c   Gutiérrez Abad, Raquel ^a,c   Bernhardt, Günther ^a   Illa, Ona ^c   Ortuño, Rosa M ^c   Cabrele, Chiara ^d   Buschauer, Armin ^a   Reiser, Oliver ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

(1,2) 2 AMINOCYCLOBUTANECARBOXYLIC ACID; (1,2) 2 AMINOCYCLOPENTANECARBOXYLIC ACID; (1,3) 3 AMINO 2,2 DIMETHYLCYCLOBUTANECARBOXYLIC ACID; CYCLOBUTANE DERIVATIVE; CYCLOPENTANE DERIVATIVE; DODECYLPHOSPHATIDYLCHOLINE; GLUTAMINE; NEUROPEPTIDE Y; PANCREAS POLYPEPTIDE; PEPTIDE FRAGMENT; PHOSPHATIDYLCHOLINE; THREONINE; UNCLASSIFIED DRUG; AMINO ACID; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICELLE; NUCLEAR MAGNETIC RESONANCE; PEPTIDE SYNTHESIS; PROTEIN BINDING; PROTEIN STRUCTURE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME SPECIFICITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

AMINO ACIDS; BINDING SITES; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEUROPEPTIDE Y; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 84887947367     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4008505     Document Type: Article

References (73)

1. Balasubramaniam, A. A. Neuropeptide Y family of hormones: Receptor subtypes and antagonists Peptides 1997, 18, 445-457
2. Cerda-Reverter, J. M.; Larhammar, D. Neuropeptide Y family of peptides: Structure, anatomical expression, function, and molecular evolution Biochem. Cell Biol. 2000, 78, 371-392
3. Cabrele, C.; Beck-Sickinger, A. G. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family J. Pept. Sci. 2000, 6, 97-122
4. Tatemoto, K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion Proc. Natl. Acad. Sci. U. S. A. 1982, 79, 2514-2518
5. Tatemoto, K.; Carlquist, M.; Mutt, V. Neuropeptide Y-A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide Nature 1982, 296, 659-660
6. Kimmel, J. R.; Hayden, L. J.; Pollock, H. G. Isolation and characterization of a new pancreatic polypeptide hormone J. Biol. Chem. 1975, 250, 9369-9376
7. Tatemoto, K.; Mutt, V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides Nature 1980, 285, 417-418
8. Balasubramaniam, A. Clinical potentials of neuropeptide Y family of hormones Am. J. Surg. 2002, 183, 430-434
9. Lin, S.; Boey, D.; Herzog, H. NPY and Y receptors: Lessons from transgenic and knockout models Neuropeptides 2004, 38, 189-200
10. Walther, C.; Mörl, K.; Beck-Sickinger, A. G. Neuropeptide Y receptors: Ligand binding and trafficking suggest novel approaches in drug development J. Pept. Sci. 2011, 17, 233-246
11. Grundemar, L.; Jonas, S. E.; Morner, N.; Hogestatt, E. D.; Wahlestedt, C.; Hakanson, R. Characterization of vascular neuropeptide Y receptors Br. J. Pharmacol. 1992, 105, 45-50
12. Wahlestedt, C.; Pich, E. M.; Koob, G. F.; Yee, F.; Heilig, M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides Science 1993, 259, 528-531
13. Pedrazzini, T.; Seydoux, J.; Kunstner, P.; Aubert, J. F.; Grouzmann, E.; Beermann, F.; Brunner, H. R. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor Nat. Med. 1998, 4, 722-726
14. Khan, I. U.; Zwanziger, D.; Bohme, I.; Javed, M.; Naseer, H.; Hyder, S. W.; Beck-Sickinger, A. G. Breast-cancer diagnosis by neuropeptide Y analogues: From synthesis to clinical application Angew. Chem., Int. Ed. 2010, 49, 1155-1158
15. Körner, M.; Reubi, J. C. NPY receptors in human cancer: A review of current knowledge Peptides 2007, 28, 419-425
16. Memminger, M.; Keller, M.; Lopuch, M.; Pop, N.; Bernhardt, G.; von Angerer, E.; Buschauer, A. The neuropeptide y y(1) receptor: A diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts PLoS ONE 2012, 7, e51032
17. Flood, J. F.; Morley, J. E. Dissociation of the effects of neuropeptide Y on feeding and memory: Evidence for pre- and postsynaptic mediation Peptides 1989, 10, 963-966
18. Potter, E. K.; Mitchell, L.; McCloskey, M. J.; Tseng, A.; Goodman, A. E.; Shine, J.; McCloskey, D. I. Pre- and postjunctional actions of neuropeptide Y and related peptides Regul. Pept. 1989, 25, 167-177
19. Illes, P.; Finta, E. P.; Nieber, K. Neuropeptide Y potentiates via Y2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurones Naunyn-Schmiedeberg's Arch. Pharmacol. 1993, 348, 546-548
20. Colmers, W. F.; Klapstein, G. J.; Fournier, A.; St-Pierre, S.; Treherne, K. A. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor Br. J. Pharmacol. 1991, 102, 41-44
21. Smith-White, M. A.; Herzog, H.; Potter, E. K. Cardiac function in neuropeptide Y Y4 receptor-knockout mice Regul. Pept. 2002, 110, 47-54
22. Lin, S.; Shi, Y. C.; Yulyaningsih, E.; Aljanova, A.; Zhang, L.; Macia, L.; Nguyen, A. D.; Lin, E. J.; During, M. J.; Herzog, H.; Sainsbury, A. Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice PLoS ONE 2009, 4, e8488
23. Kamiji, M. M.; Inui, A. Neuropeptide Y receptor selective ligands in the treatment of obesity Endocr. Rev. 2007, 28, 664-684
24. Kamiji, M. M.; Inui, A. NPY Y2 and Y4 receptors selective ligands: Promising anti-obesity drugs? Curr. Top. Med. Chem. 2007, 7, 1734-1742
25. 4 receptor-selective agonists Peptides 2007, 28, 235-240
26. Balasubramaniam, A.; Mullins, D. E.; Lin, S.; Zhai, W.; Tao, Z.; Dhawan, V. C.; Guzzi, M.; Knittel, J. J.; Slack, K.; Herzog, H.; Parker, E. M. Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): Development of an anorectic Y4 receptor selective agonist with picomolar affinity J. Med. Chem. 2006, 49, 2661-2665
27. Li, J.-B.; Asakawa, A.; Terashi, M.; Cheng, K.-C.; Chaolu, H.; Zoshiki, T.; Ushikai, M.; Sheriff, S.; Balasubramaniam, A.; Inui, A. Regulatory effects of Y4 receptor agonist (BVD-74D) on food intake Peptides 2010, 31, 1706-1710
28. Morales-Medina, J. C.; Dumont, Y.; Quirion, R. A possible role of neuropeptide Y in depression and stress Brain Res. 2010, 1314, 194-205
29. Edelsbrunner, M. E.; Painsipp, E.; Herzog, H.; Holzer, P. Evidence from knockout mice for distinct implications of neuropeptide-Y Y2 and Y4 receptors in the circadian control of locomotion, exploration, water and food intake Neuropeptides 2009, 43, 491-497
30. Painsipp, E.; Herzog, H.; Holzer, P. Evidence from knockout mice that neuropeptide-Y Y2 and Y4 receptor signalling prevents long-term depression-like behaviour caused by immune challenge J. Psychopharmacol. 2010, 24, 1551-1560
31. 4 receptor knockout mice Neuroscience 2009, 158, 1717-1730
32. 4 receptor knockout mice Genes Brain Behav. 2008, 7, 532-542
33. Marsh, D. J.; Hollopeter, G.; Kafer, K. E.; Palmiter, R. D. Role of the Y5 neuropeptide Y receptor in feeding and obesity Nat. Med. 1998, 4, 718-721
34. Marsh, D. J.; Baraban, S. C.; Hollopeter, G.; Palmiter, R. D. Role of the Y5 neuropeptide Y receptor in limbic seizures Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 13518-13523
35. 4 receptor by flow cytometry and aequorin luminescence J. Recept. Signal Transduct. 2007, 27, 217-233
36. 4 receptors in Sf9 insect cells J. Recept. Signal Transduct. 2011, 31, 271-285
37. Daniels, A. J.; Matthews, J.; Slepetis, R. J.; Jansen, M.; Viveros, O. H.; Tadapalli, A.; Harrington, W.; Heyer, D.; Landavazo, A.; Laban, J. J.; Spaltenstein, A. High-affinity neuropeptide Y receptor antagonists Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 9067-9071
38. 4 receptor agonists Eur. J. Pharmacol. 1998, 349, 97-105
39. Lindner, D.; Stichel, J.; Beck-Sickinger, A. G. Molecular recognition of the NPY hormone family by their receptors Nutrition 2008, 24, 907-917
40. Berlicki, L.; Pilsl, L.; Weber, E.; Mandity, I. M.; Cabrele, C.; Martinek, T. A.; Fulop, F.; Reiser, O. Unique alpha,beta- and alpha,alpha,beta,beta-peptide foldamers based on cis -beta- aminocyclopentanecarboxylic acid Angew. Chem., Int. Ed. 2012, 51, 2208-2212
41. De Pol, S.; Zorn, C.; Klein, C. D.; Zerbe, O.; Reiser, O. Surprisingly stable helical conformations in alpha/beta-peptides by incorporation of cis-beta-aminocyclopropane carboxylic acids Angew. Chem., Int. Ed. 2004, 43, 511-514
42. Koglin, N.; Zorn, C.; Beumer, R.; Cabrele, C.; Bubert, C.; Sewald, N.; Reiser, O.; Beck-Sickinger, A. G. Analogues of neuropeptide Y containing beta-aminocyclopropane carboxylic acids are the shortest linear peptides that are selective for the Y1 receptor Angew. Chem., Int. Ed. 2003, 42, 202-205
43. Fernandez, D.; Torres, E.; Aviles, F. X.; Ortuno, R. M.; Vendrell, J. Cyclobutane-containing peptides: Evaluation as novel metallocarboxypeptidase inhibitors and modelling of their mode of action Bioorg. Med. Chem. 2009, 17, 3824-3828
44. Gorrea, E.; Pohl, G.; Nolis, P.; Celis, S.; Burusco, K. K.; Branchadell, V.; Perczel, A.; Ortuño, R. M. Secondary structure of short beta-peptides as the chiral expression of monomeric building units: A rational and predictive model J. Org. Chem. 2012, 77, 9795-9806
45. Torres, E.; Gorrea, E.; Burusco, K. K.; Da Silva, E.; Nolis, P.; Rua, F.; Boussert, S.; Diez-Perez, I.; Dannenberg, S.; Izquierdo, S.; Giralt, E.; Jaime, C.; Branchadell, V.; Ortuno, R. M. Folding and self-assembling with beta-oligomers based on (1 R,2 S)-2-aminocyclobutane-1-carboxylic acid Org. Biomol. Chem. 2010, 8, 564-575
46. Torres, E.; Gorrea, E.; Da Silva, E.; Nolis, P.; Branchadell, V.; Ortuno, R. M. Prevalence of eight-membered hydrogen-bonded rings in some bis(cyclobutane) beta-dipeptides including residues with trans stereochemistry Org. Lett. 2009, 11, 2301-2304
47. Gorrea, E.; Nolis, P.; Torres, E.; Da Silva, E.; Amabilino, D. B.; Branchadell, V.; Ortuno, R. M. Self-assembly of chiral trans -cyclobutane-containing beta-dipeptides into ordered aggregates Chemistry 2011, 17, 4588-4597
48. 1-receptor with reduced size J. Pept. Sci. 2009, 15, 856-866
49. Cabrele, C.; Langer, M.; Bader, R.; Wieland, H. A.; Doods, H. N.; Zerbe, O.; Beck-Sickinger, A. G. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats J. Biol. Chem. 2000, 275, 36043-36048
50. Davies, S. G.; Ichihara, O.; Lenoir, I.; Walters, I. A. S. Asymmetric synthesis of (-)-(1 R,2 S)-cispentacin and related cis-and trans -2-amino cyclopentane- and cyclohexane-1-carboxylic acids J. Chem. Soc., Perkin Trans. 1 1994, 1411-1415
51. Lapatsanis, L.; Milias, G.; Froussios, K.; Kolovos, M. Synthesis of N -2,2,2-(Trichloroethoxycarbonyl)- l -amino acids and N -(9- fluorenylmethoxycarbonyl)- l -amino acids involving succinimidoxy anion as a leaving group in amino-acid protection Synthesis 1983, 671-673
52. Gutierrez-Abad, R.; Carbajo, D.; Nolis, P.; Acosta-Silva, C.; Cobos, J. A.; Illa, O.; Royo, M.; Ortuno, R. M. Synthesis and structural study of highly constrained hybrid cyclobutane-proline gamma,gamma-peptides Amino Acids 2011, 41, 673-686
53. Aguilera, J.; Moglioni, A. G.; Moltrasio, G. Y.; Ortuno, R. M. Stereodivergent and efficient synthesis of the first bis(cyclobutane) gamma-dipeptides Tetrahedron: Asymmetry 2008, 19, 302-308
54. Beumer, R.; Bubert, C.; Cabrele, C.; Vielhauer, O.; Pietzsch, M.; Reiser, O. The synthesis of diastereo- and enantiomerically pure beta- aminocyclopropanecarboxylic acids J. Org. Chem. 2000, 65, 8960-8969
55. Izquierdo, S.; Rua, F.; Sbai, A.; Parella, T.; Alvarez-Larena, A.; Branchadell, V.; Ortuno, R. M. (+)- and (-)-2-aminocyclobutane-1-carboxylic acids and their incorporation into highly rigid beta-peptides: Stereoselective synthesis and a structural study J. Org. Chem. 2005, 70, 7963-7971
56. Schneider, E.; Mayer, M.; Ziemek, R.; Li, L.; Hutzler, C.; Bernhardt, G.; Buschauer, A. A simple and powerful flow cytometric method for the simultaneous determination of multiple parameters at G-protein-coupled receptor subtypes ChemBioChem 2006, 7, 1400-1409
57. Ziemek, R.; Brennauer, A.; Schneider, E.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y(2) receptor ligands Eur. J. Pharmacol. 2006, 551, 10-18
58. 1 receptor antagonist ChemBioChem 2007, 8, 1981-1988
59. Higashijima, T.; Burnier, J.; Ross, E. M. Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activity J. Biol. Chem. 1990, 265, 14176-14186
60. Higashijima, T.; Uzu, S.; Nakajima, T.; Ross, E. M. Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins) J. Biol. Chem. 1988, 263, 6491-6494
61. Seifert, R.; Lee, T. W.; Lam, V. T.; Kobilka, B. K. Reconstitution of beta2-adrenoceptor-GTP-binding-protein interaction in Sf9 cells - high coupling efficiency in a beta2-adrenoceptor-G(s alpha) fusion protein Eur. J. Biochem. 1998, 255, 369-382
62. Beck-Sickinger, A. G.; Jung, G. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors Biopolymers 1995, 37, 123-142
63. Rist, B.; Zerbe, O.; Ingenhoven, N.; Scapozza, L.; Peers, C.; Vaughan, P. F.; McDonald, R. L.; Wieland, H. A.; Beck-Sickinger, A. G. Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor FEBS Lett. 1996, 394, 169-173
64. Leban, J. J.; Heyer, D.; Landavazo, A.; Matthews, J.; Aulabaugh, A.; Daniels, A. J. Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at the Y1-type receptor J. Med. Chem. 1995, 38, 1150-1157
65. Formaggio, F.; Peggion, C.; Crisma, M.; Kaptein, B.; Broxterman, Q. B.; Mazaleyrat, J. P.; Wakselman, M.; Toniolo, C. Recent contributions of electronic circular dichroism to the investigation of oligopeptide conformations Chirality 2004, 16, 388-397
66. Pedersen, S. L.; Bhatia, V. K.; Jurt, S.; Paulsson, J. F.; Pedersen, M. H.; Jorgensen, R.; Holst, B.; Stamou, D.; Vrang, N.; Zerbe, O.; Jensen, K. J. Improving membrane binding as a design strategy for amphipathic peptide hormones: 2-Helix variants of PYY3-36 J. Pept. Sci. 2012, 18, 579-587
67. Bader, R.; Bettio, A.; Beck-Sickinger, A. G.; Zerbe, O. Structure and dynamics of micelle-bound neuropeptide Y: Comparison with unligated NPY and implications for receptor selection J. Mol. Biol. 2001, 305, 307-329
68. Lerch, M.; Gafner, V.; Bader, R.; Christen, B.; Folkers, G.; Zerbe, O. Bovine pancreatic polypeptide (bPP) undergoes significant changes in conformation and dynamics upon binding to DPC micelles J. Mol. Biol. 2002, 322, 1117-1133
69. Martin, P.; Papayannopoulou, T. HEL cells: A new human erythroleukemia cell line with spontaneous and induced globin expression Science 1982, 216, 1233-1235
70. 5 receptor in human endometrial cancer (HEC-1B) cells Can. J. Physiol. Pharmacol. 2000, 78, 134-142
71. 2 receptors J. Pharmacol. Exp. Ther. 2007, 321, 983-995
72. Schwieters, C. D.; Kuszewski, J. J.; Tjandra, N.; Clore, G. M. The Xplor-NIH NMR molecular structure determination package J. Magn. Reson. 2003, 160, 65-73
73. Schwieters, C. D.; Kuszewski, J.; Clore, G. M. Using Xplor-NIH for NMR molecular structure determination Progr. NMR Spectrosc. 2006, 48, 47-62